Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
INTRATUMORAL ADMINISTRATION OF SIROLIMUS FOR TREATMENT OF PROSTATE CANCER
Document Type and Number:
WIPO Patent Application WO/2018/128173
Kind Code:
A1
Abstract:
The present disclosure relates to methods of treating prostate cancer by administering an effective amount of sirolimus locally to the prostate of a subject in need thereof. In particular, the present disclosure provides methods of treating prostate cancer by intratumoral injection of a liquid formulation comprising sirolimus in which the amount of sirolimus administered is well above the dosage used for preventing transplant rejection.

Inventors:
KUNDU AISHWARYA (US)
ESCUDERO CECILE (US)
MUDUMBA SREENIVASU (US)
Application Number:
PCT/JP2017/047408
Publication Date:
July 12, 2018
Filing Date:
December 29, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SANTEN PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/436; A61K9/08; A61K45/00; A61K47/10; A61K47/18; A61K47/20; A61K47/22; A61K47/24; A61K47/26; A61K47/34; A61K47/36; A61P35/00
Domestic Patent References:
WO2007092620A22007-08-16
WO2008109163A12008-09-12
Foreign References:
US20050222191A12005-10-06
Other References:
ARMSTRONG, A. J. ET AL.: "A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer", CLIN. CANCER RES., vol. 16, no. 11, 2010, pages 3057 - 3066, XP055509747
AMATO, R. J. ET AL.: "Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer", CLIN. GENITOURIN. CANCER, vol. 6, no. 2, 2008, pages 97 - 102, XP055509916
MORIKAWA, Y. ET AL.: "Rapamycin enhances docetaxel -induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 419, 2012, pages 584 - 589, XP055509918
IMRALI, A. ET AL.: "Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin", AM. J. CANCER RES., vol. 6, no. 8, 2016, pages 1772 - 1784, XP055509927
FAGONE, P. ET AL.: "Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells", BASIC CLIN. PHARMACOL. TOXICOL., vol. 112, 2013, pages 63 - 69, XP055509934
GOLDBERG, E. P. ET AL.: "Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery", J. PHARM. PHARMACOL., vol. 54, 2002, pages 159 - 180, XP055509937
SHIKANOV, S. ET AL.: "Intratumoral Delivery of Paclitaxel for Treatment of Orthotopic Prostate Cancer", J. PHARM. SCI., vol. 98, 2009, pages 1005 - 1014, XP055509946
See also references of EP 3565553A4
Attorney, Agent or Firm:
HARAKENZO WORLD PATENT & TRADEMARK (JP)
Download PDF: